Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering

• Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology 

• CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity

AMSTERDAM, THE NETHERLANDS October 18^th, 2022 — Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® metal-free click chemistry.

Under the terms of the agreement, Synaffix will obtain exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology. This further expands the GlycoConnect™ ADC tool kit by significantly enhancing the versatility across cytotoxic payloads and supports further expansion into antibody-based targeted gene therapy and immune cell engager applications.

Floris van Delft, Chief Scientific Officer of Synaffix, said: "We are impressed by the properties of CliCr®, which clearly demonstrate best-in-class potential as chemistry for metal-free click conjugation with azides. In that respect, CliCr® combines perfectly with our GlycoConnect™ technology for ADCs, not only by allowing highly rapid conjugation with minimal linker-drug excess and thus lowering COGs, but also by further expanding the repertoire of payloads suitable for conjugation. This deal comes at an exciting time, as we have recently seen the Noble Prize of Chemistry, awarded for ‘the development of click chemistry’, enabling companies like Synaffix to develop best-in-class drug candidates for oncology and other indications."

Cristianne Rijcken, Chief Scientific Officer of Cristal Therapeutics stated: “We are emboldened by this license agreement with Synaffix, a leading provider of ADC technology, as it underscores the potential of our unique CliCr® technology. This also represents an important milestone in the execution of our strategy to commercialize CliCr® in different fields of therapeutic bioconjugates.”